Astrazeneca (AZN) Short-term Investments (2009 - 2026)

Astrazeneca's Short-term Investments history runs 18 years deep, the most recent figure standing at $76.0 million for Q2 2026.

• In Q2 2026, Short-term Investments fell 20.0% year-over-year to $76.0 million; the TTM figure through Jun 2026 stood at $76.0 million (down 20.0% YoY), while the FY2025 annual figure was $90.0 million, down 45.78% from the prior year.
• Short-term Investments for Q2 2026 stood at $76.0 million, down from $2.4 billion in the prior quarter.
• The five-year high for Short-term Investments was $2.4 billion in Q1 2026, with the low at $76.0 million in Q2 2026.
• The 5-year median for Short-term Investments is $1.1 billion (2022), against an average of $1.0 billion.
• The sharpest annual moves came in 2022 and 2025: Short-term Investments soared 187.95% in 2022, then plunged 94.09% in 2025.
• Astrazeneca's Short-term Investments stood at $239.0 million in 2022, then tumbled by 48.95% to $122.0 million in 2023, then soared by 36.07% to $166.0 million in 2024, then plunged by 45.78% to $90.0 million in 2025, then dropped by 15.56% to $76.0 million in 2026.
• Business Quant data shows AZN's Short-term Investments at $76.0 million in Q2 2026, $2.4 billion in Q1 2026, and $90.0 million in Q4 2025.